Biofrontera Inc. BFRIW
Set alert
As of Oct 30, 3:57 PM ET
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0971
- Prev close
- 0.0014
- Mkt cap
- 796.65K
- Vol
- 37.97K
- Avg vol
- 0
- EPS
- -1.30
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0014
- High
- 0.0014
- Forward P/E
- 0.00
- Beta
- 0.51
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.04
- EPS (TTM)
- -1.30
- Beta
- 0.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -38.34%
- Revenue (TTM)
- 35.24M
- Revenue growth
- 34.00%
- Free cash flow
- -17.96M
- Total cash
- 4.39M
- Total debt
- 1.44M
- Return on equity
- -149.41%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- biofrontera-us.com
News
- Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
- Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
- Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
- Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Your note
Sign in to keep a note on BFRIW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bard Associates Inc. | 5.80% | 179,900 | 21.59K | Sep 29, 2024 |
| Clear Street LLC | 0.35% | 10,789 | 1.29K | Sep 29, 2024 |
| UBS Group AG | 0.20% | 6,324 | 758 | Sep 29, 2024 |
| Osaic Holdings Inc | 0.04% | 1,100 | 131 | Sep 29, 2024 |
| U.S. Bancorp\DE\ | 0.03% | 1,000 | 119 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 100 | 11 | Sep 29, 2024 |